Moderna’s cancer vaccine programme now stretches into pancreatic cancer, yet the fresh Phase I data presented at ESMO do nothing to settle the larger question hanging over the stock: how far the clinical momentum behind intismeran autogene can actually travel. The early-stage trial covers adjuvant use in resectable ductal adenocarcinoma of the pancreas, adding a second tumour type to a programme already anchored in melanoma. Investors would be wrong to read that widening of the clinical map as proof the melanoma success will simply repeat itself.
A Phase I study and a Phase III trial do not belong in the same valuation bucket. Lumping both together under the loose label of “cancer vaccine data” blurs the very different stages of development behind them. The pancreatic programme is a prospect, not a substitute for judging each study on its own evidence.
Strong Data, Weak Share Price
Thursday offered a sharp lesson in how far clinical results and shareholder expectations can drift apart. Merck and Moderna released the full findings from the Phase III INTerpath-001 trial, and the numbers were solid. After a median follow-up of 24.6 months, the combination of intismeran autogene and Keytruda cut the risk of melanoma recurrence or death by 42% versus Keytruda alone. The risk of distant metastasis or death fell by 38%.
The statistical backing was firm: a hazard ratio of 0.58 and a p-value below 0.001 for the recurrence-or-death endpoint, with a p-value of 0.002 on distant metastasis or death. Those figures measure a risk reduction against the comparator arm. They are not a cure guarantee, nor do they say how much any single patient stands to gain, and the added benefit cannot be credited to intismeran alone without naming the Keytruda combination that was actually tested.
What followed was a steep sell-off, which Reuters linked to profit-taking after the data were published ahead of schedule following a leak. Media reports suggested the distant-metastasis result in particular fell short of expectations built up by earlier study data. A share-price reaction answers a different question than a clinical trial does, and it cannot invalidate the treatment effects that were measured.
Should investors sell immediately? Or is it worth buying Moderna?
Approval Is a Forecast, Not a Fact
According to media reports, Moderna chief executive Stéphane Bancel said the company and Merck are pressing hard on a filing for FDA approval and that he expects a green light in 2027. The partners are also preparing tests in additional cancer types. Both are relevant to the investment case, but they sit in a different category from the data: an expected approval remains an expectation, and planned trials in other tumours are not yet evidence of efficacy in those settings.
That distinction is where the valuation should draw its line. The melanoma results are a persuasive argument for the combination’s clinical potential. They do not justify booking an approval and a string of further indications as already secured.
The Next Financial Checkpoint
Moderna plans to report third-quarter 2026 results and hold a conference call on 6 November 2026, giving investors their next financial reference point alongside the clinical news flow. The stock should be judged neither by the recent price move nor by the melanoma programme in isolation. What matters is keeping the stages of development apart — and refusing to confuse an added scientific prospect with a demonstrated success.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from October 27 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 27.
Moderna: Buy or sell? Read more here...
